UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 1121, 2016

Tribute Pharmaceuticals Canada Inc.

(Exact name of registrant as specified in its charter)

Ontario, Canada		000-31198		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1

(Address of principal executive offices) (Zip Code)

(905) 876-1118

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01

Regulation FD Disclosure.

On January 1121, 2016, Tribute Pharmaceuticals Canada Inc. (“Tribute”) issued a press release announcing ~~the~~that ~~mailing~~Institutional ofShareholder ~~materials~~Services toand ~~its~~Glass Lewis & Co. have both recommended that Tribute shareholders invote ~~connection~~FOR the special resolution to approve the previously announced transaction with POZEN Inc. (“POZEN”) and combination under Aralez Pharmaceuticals Inc. (“Aralez”), to be considered at the upcoming special meeting of Tribute shareholders being held on ~~Monday,~~ February 1, 2016. The full text of the press release is being furnished as Exhibit 99.1 to this Form 8-K, and shall not be deemed filed under the Securities Exchange Act of 1934, as amended.

Item 8.01 Other Events.

Certain materials mailed by Tribute to its shareholders on January 11, 2016 in connection with such special meeting of shareholders are filed under Item 9.01 herewith.

Additional Information and Where to Find It

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ ARALEZ ~~PHARMACEUTICALS INC.~~’S ~~(“ARALEZ”)~~ REGISTRATION STATEMENT ON FORM S-4 AND POZEN ~~INC.~~’S ~~(“POZEN”)~~ RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS AS WELL AS TRIBUTE’S INFORMATION CIRCULAR BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ARALEZ, POZEN, TRIBUTE AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents and other related documents filed with the United States Securities and Exchange Commission (“SEC”) at the SEC’s website at www.sec.gov. Investors and security holders ~~will~~may ~~be able to~~ obtain free copies of the Information Circular and other documents filed by Tribute on the System for Electronic Document Analysis Retrieval (“SEDAR”) website maintained by the Canadian Securities Administrators at www.sedar.com and on the SEC’s website at www.sec.gov. Investors and security holders may obtain free copies of the documents filed by POZEN with the SEC on POZEN’s website at www.pozen.com under the heading “Investors” and then under the heading “SEC Filings” and free copies of the documents filed by Tribute with the SEC on Tribute’s website at www.tributepharma.com under the heading “Investors” and then under the heading “SEC Filings.”

POZEN, Tribute and Aralez and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of POZEN and shareholders of Tribute and Aralez in connection with the proposed transaction. Information regarding the special interests, if any, of these directors and executive officers in the proposed transaction is included in the proxy statement/prospectus and Information Circular described above. Additional information regarding the directors and executive officers of POZEN and Tribute is contained in their respective annual reports on Form 10-K for the year ended December 31, 2014 filed with the SEC.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Item 9.01

Financial Statements and Exhibits.

d) Exhibits

Exhibit No.		Description
99.1		Press Release dated January 11, 2016
99.2		Notice of Special Meeting and Management Information Circular dated January 5, 2016
99.3		Letter of Transmittal
99.4		Form of Proxy

The following exhibit is furnished herewith:

Exhibit No.		Description
99.1		Press release dated January 21, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TRIBUTE PHARMACEUTICALS CANADA INC.
Date: January 11, 2016	By:	/s/ Scott Langille
Date: January 21, 2016	By:	/s/ Scott Langille
	Name:	Scott Langille
	Name: Scott Langille
	Title:	Chief Financial Officer
	Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press ~~Release~~release dated January 1121, 2016.
99.2		Notice of Special Meeting and Management Information Circular dated January 5, 2016
99.3		Letter of Transmittal
99.4		Form of Proxy

Filing Compare · Tribute Pharmaceuticals Canada Inc.